文献速递膀胱癌与上尿路尿路上皮癌

九十岁以上膀胱癌患者的多中心研究:123例分析

Bladder cancer in nonagenarians: a multicentre study of 123 patients.
PubMed 文献 · BJU Int · 2018-07-26

本研究回顾性分析了2006至2016年间123例年龄≥90岁的膀胱癌患者,平均年龄91岁。结果显示pTa、pT1和≥pT2期肿瘤分布几乎均匀,67.5%患者经尿道膀胱肿瘤电切术后无复发,中位总生存期在pTa、pT1和≥pT2期分别为30.0、14.0和6.0个月。

要点

  • 九十岁以上膀胱癌患者分期分布均匀,pTa占39%,pT1占28.5%,≥pT2占33%。
  • 经尿道膀胱肿瘤电切术后67.5%无复发,pTa复发率42%,pT1为34%,≥pT2为15%。
  • 中位总生存期随分期升高而降低,pTa为30.0个月,pT1为14.0个月,≥pT2为6.0个月。

核心结论

  • 在九十岁以上膀胱癌患者中,pTa/pT1/≥pT2分期几乎均匀分布,三分之二患者经尿道膀胱肿瘤电切术后无复发。
  • 中位总生存期总体为1.3年,≥pT2期患者仅6个月。

研究设计与样本

  • 回顾性多中心研究,纳入2006年1月1日至2016年12月31日期间在参与中心治疗的年龄≥90岁膀胱癌患者,共123例,平均年龄91岁(范围90-99岁)。
  • 患者包括新发或复发癌症,收集人口统计学、肿瘤特征、治疗策略和结局数据。

主要发现

  • ASA评分分布:II级38%,III级50%,IV级12%;男女比例2.4:1。
  • 60%患者为新发癌症诊断;组织学显示pTa 39%(n=48),pT1 28.5%(n=35),≥pT2 33%(n=40)。
  • 总体67.5%患者无复发,25.2%复发一次,7.5%复发两次或以上。
  • pTa肿瘤(n=48)复发20例(42%),pT1(n=35)复发12例(34%),≥pT2(n=40)复发6例(15%)。
  • 中位总生存期:pTa 30.0个月,pT1 14.0个月,≥pT2 6.0个月;总死亡率pTa 40%,pT1 60%,≥pT2 75%。

临床怎么用

  • 对于九十岁以上膀胱癌患者,经尿道膀胱肿瘤电切术可使多数患者获得无复发状态,但需根据分期和ASA评分评估预后。

局限性

  • 需要更多针对该特定年龄组的病例系列研究以确定最佳管理策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the oncological outcome of nonagenarians with bladder cancer, as a substantial rise in bladder cancer in the old-old age group in the upcoming decades is expected, due to demographic changes and the peak incidence around the age of 85 years. The paucity of data of nonagenarians prompted us to investigate the outcomes of such patients. PATIENTS AND METHODS: A retrospective, multicentre study was designed to assess patient demographics, tumour patterns, treatment strategies and outcome in patients aged ≥90 years treated at participating centres. Patients entered either as de novo or as recurrent cancer. The study period ranged from 01.01.2006 to 31.12.2016. RESULTS: A total of 123 patients with a mean (range) age of 91 (90-99) years were recruited. The American Society of Anesthesiologists Physical Status Classification (ASA-score) distribution was as follows: II, 38%; III, 50%; IV, 12%; and the male to female ratio 2.4:1. The median (range) follow-up was 8 (1-132) months. In all, 60% of patients had a de novo cancer diagnosis. Histological findings revealed: pTa 39% (n = 48), pT1 28.5% (n = 35), and ≥pT2 33% (n = 40). Overall, 67.5% patients had no recurrence, 25.2% one and 7.5% two or more. pTa tumours (n = 48) recurred in 20 patients (42%), pT1 tumours (n = 35) in 12 (34%), and ≥pT2 tumours (n = 40) in six (15%). The median overall survival (OS) was 30.0 months for patients with pTa tumours, 14.0 months for pT1 tumours, and 6.0 months for ≥pT2 tumours. The overall mortality rate of patients with pTa tumours was 40%, with pT1 tumours at 60%, and ≥pT2 tumours 75%. The ASA-score also had a strong influence on median OS after stratification by ASA-score (II, 30 months; III, 12 months; IV, 4 months). CONCLUSIONS: In nonagenarians with bladder tumours, pTa/pT1/≥pT2 stages are almost evenly distributed and two-thirds of patients had no recurrence after transurethral resection of the bladder. The mean OS was 1.3 years, and 6 months for ≥pT2 tumours. Further case-series of patients in this specific age-group are required to identify the best management of this increasing proportion of patients with bladder tumours.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Eredics K, Bretterbauer KM, Comploj E, et al. Bladder cancer in nonagenarians: a multicentre study of 123 patients. BJU Int. 2018. PMID: 29804311. doi:10.1111/bju.14419

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。